Compare Amylx Pharmaceuticals Inc (AMLX) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Extra Space Storage, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.73 (market cap $2.64B), while Extra Space Storage, Inc. trades at $145.67 (market cap $30.96B). The key difference: Extra Space Storage, Inc. is far larger — about 11.7× Amylx Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EXR | |
|---|---|---|
Market Cap | $2.64B | $30.96B |
Sector | Health | Real Estate |
52-Week High | $24.19 | $152.85 |
52-Week Low | $7.82 | $126.67 |
Enterprise Value | $2.39B | $44.68B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Extra Space Storage (EXR) trades at $146.66, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, with revenue growth and solid same-store NOI performance. Analyst consensus is a 'Hold' with a $157.25 price target, indicating modest upside potential from current levels.
Outlook remains stable with steady revenue and earnings growth supported by acquisitions and resilient demand, though new supply and higher debt pose headwinds. Risks include competitive pressures and interest rate sensitivity, but the secure 4.3% dividend yield and strong balance sheet provide downside protection for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
